Autoimmune Diseases

Disease State Hub

FDA Alerts

Autoimmune diseases

FDA Approves First Treatment for Rare Autoimmune disease

12/12/2017

The US Food and Drug Administration has recently approved the first treatment option for patients with eosinophilic granulomatosis with polyangiitis.

12/12/2017

Research Summaries

Research summary

Early Serologic Diagnosis of AQP4+ NMOSD Based on Clinical Factors

08/22/2024

Jessica Ganga

In a multicenter, retrospective study, researchers evaluated time from NMOSD onset to serological diagnosis and factors associated with predicting shorter time to diagnosis.

08/22/2024

Research Summary

Meta-Analysis Highlights Clinical Differences Between Patients With NMOSD, MS

06/11/2024

Anthony Calabro, MA

A systematic review and meta-analysis examined the clinical differences between adult patients with neuromyelitis optica spectrum disorders and those with multiple sclerosis.

06/11/2024

Autoimmune diseases

Ursodeoxycholic Acid May Improve OS Among African Americans With PBC

01/27/2020

Using data from the Fibrotic Liver Disease Consortium, authors of a new study evaluated ursodeoxycholic acid’s impact on patients with primary biliary cholangitis and whether the effects differ across...

01/27/2020

Autoimmune diseases

FDA Approves First Treatment for Rare Autoimmune disease

12/12/2017

The US Food and Drug Administration has recently approved the first treatment option for patients with eosinophilic granulomatosis with polyangiitis.

12/12/2017

Research Summary

Research Summary

Do Patients with Neuromyelitis Optica Spectrum Disorder Experience Prodromal Neurologic Symptoms Preceding Their First Attack?

10/01/2015

Miranda Manier, BA

Researchers found that approximately 1 in 7 patients with aquaporin-4 antibody positive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD) experienced neurologic symptoms before their first attack. ...

10/01/2015

October 2024

Current Issue

October 2024

Volume 64

Issue 9